Stopping Ocrevus in stable MS doesn’t seem to raise 2-year risk, study finds
But patients should restart treatment after 2.5 years or disease activity Written by Marisa Wexler, MS | March 17, 2026 For people with multiple…
Ocrevus and Tysabri appear to work equally well to control relapsing MS
Danish study finds no difference in relapse rates or disease progression Written by Margarida Maia, PhD | February 26, 2026 Ocrevus and Tysabri…
Stuart Schlossman
Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.
More than 2 years after its original approval, Sandoz’ natalizumab (Tyruko) biosimilar is officially available to patients with multiple sclerosis…
Stuart Schlossman
Do you Know about the 2-TIMES-A-YEAR* OCREVUS and its AVAILABILITY for treating RMS and PPMS TWO different ways?
As a ~10-minute† subcutaneous injection OR as a 4-hour†/2-hour†‡ intravenous infusion To Learn More, click here: www.ocrevus.com…
Stuart Schlossman
